人工智能全自动量化68Ga-PSMA-11 PET肿瘤负荷预测177Lu-PSMA治疗后生存
该回顾性队列纳入107例接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌患者,利用深度学习在基线68Ga-PSMA-11 PET/CT上自动分割PSMA阳性病灶并计算肿瘤负荷指标。PSMATV、PSMATU和PSMATQ升高均与总生存缩短显著相关,整合PSMATQ与临床因素的列线图 bootstrap校正C-index为0.71,低危组中位OS 30.9个月显著长于高危组7.9个月。
要点
- AI自动分割PSMA PET得出的PSMATV、PSMATU、PSMATQ升高与更短OS显著相关。
- 整合PSMATQ与化疗史、血红蛋白、碱性磷酸酶、PSA的列线图C-index为0.71。
- 列线图低危组中位OS 30.9个月,高危组7.9个月,HR 0.25。
核心结论
- 基于PSMA PET的AI肿瘤负荷体积分析对177Lu-PSMA治疗的mCRPC患者生存具有预后价值。
- 整合PSMATQ与临床因素的列线图可能有助于个体化风险分层和AI辅助治疗决策。
研究设计与样本
- 回顾性队列研究,纳入107例连续接受177Lu-PSMA治疗的mCRPC患者。
- 采用深度学习算法在基线68Ga-PSMA-11 PET/CT上自动勾画PSMA阳性病灶。
- 由分割病灶衍生PSMATV、PSMATU(PSMATV×SUVmean)和PSMATQ(PSMATV/SUVmean)。
- 通过Cox回归分析构建预后列线图,并采用LASSO正则化进行变量选择。
主要发现
- 单因素分析显示较高的PSMATV(HR 1.26)、PSMATU(HR 1.18)和PSMATQ(HR 1.29)与更短总生存显著相关。
- 整合PSMATQ、化疗史、血红蛋白、碱性磷酸酶和前列腺特异性抗原的列线图bootstrap校正C-index为0.71(95% CI 0.64-0.78)。
- 列线图风险分层显示低危组较高危组OS显著延长(中位OS 30.9 vs. 7.9个月;HR 0.25,95% CI 0.13-0.45,P < 0.001)。
关键数值与推荐
- PSMATV每单位升高HR 1.26,PSMATU每单位升高HR 1.18,PSMATQ每单位升高HR 1.29,均与更短OS显著相关。
- 列线图bootstrap校正C-index为0.71(95% CI 0.64-0.78)。
- 低危组与高危组中位OS分别为30.9个月和7.9个月,HR 0.25(95% CI 0.13-0.45,P < 0.001)。
临床怎么用
- 可在基线68Ga-PSMA-11 PET/CT上使用AI自动分割量化肿瘤负荷,辅助预测177Lu-PSMA治疗后的生存。
- 可将PSMATQ与化疗史、血红蛋白、碱性磷酸酶和PSA整合用于风险分层,辅助个体化治疗决策。
局限性
- 回顾性设计是本研究局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite the rapid development of artificial intelligence (AI)-powered automated segmentation tools for PET/CT imaging, their prognostic value in predicting survival outcomes remains inadequately assessed. Our objective was to explore the prognostic significance of tumor burden quantification derived from PSMA PET/CT using AI for metastatic castration-resistant prostate cancer (mCRPC) patients receiving Lutetium-177 (¹⁷⁷Lu) PSMA therapy. METHODS: A retrospective cohort of 107 consecutive patients with mCRPC treated with ¹⁷⁷Lu-PSMA therapy were analyzed. Utilizing a deep learning algorithm, PSMA-positive lesions were automatically delineated on baseline 68Ga-PSMA-11 PET/CT scans. Key metrics were derived from the segmented lesions: total tumor volume (PSMATV), total tumor load (PSMATU = PSMATV × SUVmean), and total tumor quotient (PSMATQ = PSMATV / SUVmean). A prognostic nomogram was developed through Cox regression analysis, incorporating LASSO regularization for variable selection. RESULTS: Univariate analysis revealed that higher PSMATV (HR 1.26), PSMATU (HR 1.18), and PSMATQ (HR 1.29) were significantly associated with shorter overall survival (OS). A prognostic nomogram that integrated PSMATQ alongside chemotherapy history, hemoglobin levels, alkaline phosphatase, and prostate-specific antigen demonstrated a bootstrap-corrected C-index of 0.71 (95% CI 0.64-0.78). Risk stratification using the nomogram showed significantly prolonged OS in low-risk vs. high-risk groups (median OS 30.9 vs. 7.9 months; HR 0.25, 95% CI 0.13-0.45, P < 0.001). The retrospective design is a study limitation. CONCLUSION: AI-based volumetric analysis of tumor burden on PSMA PET has prognostic significance for survival in ¹⁷⁷Lu-PSMA-treated mCRPC patients. The nomogram integrating PSMATQ with clinical factors might help in personalized risk stratification, facilitating AI-aided therapeutic decision-making.
引用
- Zang S, Meng Q, Li X, et al. Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic Castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 41111086. doi:10.1007/s00259-025-07628-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。